What is the 13F Pro Quality Score for VRTX?

13F Pro ranks VERTEX PHARMACEUTICALS INC / MA (VRTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VRTX's current score at https://13fpro.ai/research/VRTX (free sign-up required for the full ranking).

Where does 13F Pro source VRTX data?

All VERTEX PHARMACEUTICALS INC / MA fundamentals and ownership data come directly from SEC EDGAR. VERTEX PHARMACEUTICALS INC / MA files with the SEC under CIK 875320. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VRTX in?

VERTEX PHARMACEUTICALS INC / MA (VRTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives VRTX's revenue?

Per VERTEX PHARMACEUTICALS INC / MA's latest 10-Q filed with the SEC on 2026-05-05, the biggest revenue drivers are: Cystic Fibrosis Products ($2,915.0M, +6% YoY); CASGEVY ($42.9M, +202% YoY); JOURNAVX ($29.0M, Not disclosed). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/VRTX.

What are VRTX's largest expenses?

VERTEX PHARMACEUTICALS INC / MA's latest 10-Q reports these as the largest expense items: Research and Development ($961.6M, -2% YoY); Selling, General and Administrative ($493.7M, +25% YoY); Cost of Sales ($392.8M, +8% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is VRTX research updated on 13F Pro?

VRTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VERTEX PHARMACEUTICALS INC / MA(VRTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 875320 VRTX stock profile & AI dashboard →

13F Pro Quality Score

76.6/100

Rank #101 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

61.2/100

Profitability

92.6/100

Balance Sheet

93.0/100

Earnings Quality

39.6/100

Free Cash Flow

88.4/100

Institutional Flow

46.1/100

Revenue Scale

87.9/100

Dilution Risk

23.8/100

VRTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for VERTEX PHARMACEUTICALS INC / MA (VRTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRTX at 76.6/100 on a 32-signal composite quality model, placing it at rank #101 of 2,879 stocks — the top 5% of the AI-ranked universe. VRTX scores in the top quartile across balance sheet strength (93.0), profitability (92.6), free cash flow (88.4). Areas of concern include earnings quality (39.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), VERTEX PHARMACEUTICALS INC / MA reports quarterly revenue of $3.0B, net income of $1.0B, an operating margin of 38.1%. Top institutional holders of VRTX by reported 13-F value include Capital World Investors, BlackRock,, Capital Research Global Investors, based on the most recent SEC filings. VRTX trades on the Nasdaq exchange and files with the SEC under CIK 875320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERTEX PHARMACEUTICALS INC / MA directly from SEC EDGAR. VERTEX PHARMACEUTICALS INC / MA's 13F Pro composite quality score has ranged between 8 and 87 since 2021, currently 76.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about VERTEX PHARMACEUTICALS INC / MA

Quirks, history, and lore behind VRTX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · large-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue around $10 billion with operating margins that make most pharma companies jealous — north of 40% — built almost entirely on a single disease area.
3
The History
Founded in 1989, it spent decades as a research-stage company before cracking one of medicine's toughest nuts: a genetic disease once thought essentially untreatable.
4
The Secret
It doesn't treat symptoms — it targets the underlying protein defect caused by mutations in a single gene, a landmark shift in how rare genetic diseases are approached.
5
The Lore
Its blockbuster combo therapy Trikafta was called a near-miracle by patient groups and transformed the life expectancy outlook for people with a chronic lung disease affecting tens of thousands in the U.S.
6
The Giveaway
The dominant force in cystic fibrosis treatments, its modulators reach the vast majority of CF patients eligible for therapy — and it's now pushing into pain, kidney disease, and gene editing.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving VRTX's Business? Latest 10-Q Breakdown

AI-extracted from VERTEX PHARMACEUTICALS INC / MA's 10-Q filed 2026-05-05 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Vertex Q1 2026 net product revenues grew 8% YoY to $2.99B, driven by TRIKAFTA, ALYFTREK, CASGEVY and JOURNAVX, with net income of $1.03B up 60% YoY.

Biggest Revenue Drivers

Total revenue: $2,986.9M+8% YoY

Cystic Fibrosis Products$2,915.0M+6% YoY

Continued performance of CF therapies; TRIKAFTA/KAFTRIO revenue of $2,354.7M down 7% but offset by ALYFTREK growth of 687% to $424.4M.

CASGEVY$42.9M+202% YoY

Sickle cell disease and beta thalassemia; secured pricing agreement in Germany and pediatric submission in U.S.

JOURNAVX$29.0MNot disclosed

Acute pain product launched March 2025; over 350,000 prescriptions filled in Q1 2026; new Medicare Part D coverage agreement effective May 1.

Largest Expense Items

Research and Development$961.6M-2% YoY

Investment in pipeline including cell and genetic therapy; development expenses of $756.6M reflect mid- and late-stage programs for povetacicept, T1D, peripheral neuropathic pain and AMKD.

Selling, General and Administrative$493.7M+25% YoY

Increased internal headcount and commercial investment to support JOURNAVX and povetacicept in IgAN.

Cost of Sales$392.8M+8% YoY

Cost as percentage of net product revenues 13.2% in both Q1 2026 and Q1 2025; third-party royalties on CF products offset by product mix changes.

Watch Items from the Filing

ALYFTREK royalty dispute: Royalty Pharma initiated arbitration October 2025 claiming royalty burden on ALYFTREK is ~8% versus Vertex's position of 4%; total ALYFTREK net sales to date $1.3B; outcome could materially impact future margins.
New product launches gaining momentum: JOURNAVX filled >350k prescriptions in Q1 2026 post-launch (March 2025); CASGEVY revenues up 202% YoY to $42.9M; povetacicept BLA submitted March 2026 for IgAN with expedited 6-month FDA review timeline.
Strong cash position and deployment: Cash, equivalents and marketable securities increased to $13.0B as of March 31 2026 from $12.3B at year-end; $3.0B remaining on May 2025 authorized share repurchase program.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$3.0B

Net Income

Q1 2026

$1.0B

Free Cash Flow

Q1 2026

$1.3B

Operating Margin

Q1 2026

38.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.9% YoY

$12.00BFY 2025

FY22 $8.93BFY23 $9.87BFY24 $11.02BFY25 $12.00B

Net Income

+838.1% YoY

$3.95BFY 2025

FY22 $3.32BFY23 $3.62BFY24 $-535.6MFY25 $3.95B

Operating Income

+1891.9% YoY

$4.17BFY 2025

FY22 $4.31BFY23 $3.83BFY24 $-232.9MFY25 $4.17B

EPS (Diluted)

+836.5% YoY

$15.32FY 2025

FY22 $12.82FY23 $13.89FY24 $-2.08FY25 $15.32

Total Assets

+13.8% YoY

$25.64BFY 2025

FY22 $18.15BFY23 $22.73BFY24 $22.53BFY25 $25.64B

Op. Cash Flow

+837.2% YoY

$3.63BFY 2025

FY22 $4.13BFY23 $3.54BFY24 $-492.6MFY25 $3.63B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$12.00B +8.9%	$11.02B +11.7%	$9.87B +10.5%	$8.93B +17.9%	$7.57B +82.0%	$4.16B
Net Income	$3.95B +838.1%	$-535.6M -114.8%	$3.62B +9.0%	$3.32B +41.8%	$2.34B +99.0%	$1.18B
Operating Income	$4.17B +1891.9%	$-232.9M -106.1%	$3.83B -11.0%	$4.31B +54.8%	$2.78B +132.3%	$1.20B
EPS (Diluted)	$15.32 +836.5%	$-2.08 -115.0%	$13.89 +8.3%	$12.82 +42.3%	$9.01 +99.8%	$4.51
Total Assets	$25.64B +13.8%	$22.53B -0.9%	$22.73B +25.2%	$18.15B +35.1%	$13.43B +61.5%	$8.32B
Operating Cash Flow	$3.63B +837.2%	$-492.6M -113.9%	$3.54B -14.3%	$4.13B +56.2%	$2.64B +68.5%	$1.57B

AI Insight: VRTX Financial Trends

Revenue growth momentum accelerated through 2025 but Q1 2026 showed first sequential decline in over a year.

• Revenue grew from $2,646M in Q2 2024 to $3,190M in Q4 2025, representing 20.6% growth over six quarters.

• Operating income turned positive after Q2 2024's -$3,515M loss, stabilizing around $1,100M-$1,200M range through 2025.

• Equity strengthened consistently from $14,775M in Q2 2024 to $19,362M in Q1 2026.

⚠ Revenue declined 6.4% sequentially in Q1 2026 to $2,987M after four consecutive quarters of growth.

⚠ Operating cash flow remains volatile, dropping to $498M in Q4 2025 before rebounding to $1,428M in Q1 2026.

AI Insight: VRTX Ratio Trends

Vertex shows strong profitability recovery from Q2 2024 lows, with operating margins stabilizing above 37% through Q1 2026.

• Operating margin rebounded from -132.8% in Q2 2024 to 38.1% in Q1 2026, indicating strong operational recovery.

• ROE recovered from -97.3% in Q2 2024 to 21.3% in Q1 2026, though below the 25%+ levels seen in Q2-Q4 2025.

• ROIC stabilized around 23-27% range after bottoming at -95.2% in Q2 2024, demonstrating improved capital efficiency.

⚠ ROE declined from 25.5% in Q4 2025 to 21.3% in Q1 2026, breaking four-quarter improvement streak.

⚠ Net profit margin dipped from 37.3% in Q4 2025 to 34.5% in Q1 2026, suggesting potential margin pressure.

Get alerted when VRTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VERTEX PHARMACEUTICALS INC / MA including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VRTX

Capital World Investors
$11.3B25,368,124 sh
BlackRock, Inc.
$10.7B23,969,517 sh
Capital Research Global Investors
$9.4B21,125,964 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.4B16,512,810 sh
STATE STREET CORP
$5.2B11,730,139 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.7B6,139,621 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.3B5,145,609 sh
Capital International Investors
$2.3B5,126,077 sh
LOOMIS SAYLES & CO L P
$1.8B4,003,821 sh
ALLIANCEBERNSTEIN L.P.
$1.8B3,910,786 sh

Fund	Value	Shares
Capital World Investors	$11.3B	25,368,124
BlackRock, Inc.	$10.7B	23,969,517
Capital Research Global Investors	$9.4B	21,125,964
VANGUARD CAPITAL MANAGEMENT LLC	$7.4B	16,512,810
STATE STREET CORP	$5.2B	11,730,139
GEODE CAPITAL MANAGEMENT, LLC	$2.7B	6,139,621
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.3B	5,145,609
Capital International Investors	$2.3B	5,126,077
LOOMIS SAYLES & CO L P	$1.8B	4,003,821
ALLIANCEBERNSTEIN L.P.	$1.8B	3,910,786

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VRTX on your watchlist

Track score changes the day VERTEX PHARMACEUTICALS INC / MA files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VRTX a good stock to buy?

13F Pro's AI-powered analysis of VERTEX PHARMACEUTICALS INC / MA (VRTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VRTX are available on the VRTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VRTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VRTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VERTEX PHARMACEUTICALS INC / MA's investment landscape.